Literature DB >> 19072991

Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test.

Lyn Schofield1, Natasha Watson, Fabienne Grieu, Wei Qi Li, Nik Zeps, Jennet Harvey, Colin Stewart, Michael Abdo, Jack Goldblatt, Barry Iacopetta.   

Abstract

Approximately 1-2% of colorectal cancers (CRC) arise because of germline mutations in DNA mismatch repair genes, referred to as Lynch syndrome. These tumours show microsatellite instability (MSI) and loss of expression of mismatch repair proteins. Pre-symptomatic identification of mutation carriers has been demonstrated to improve survival; however, there is concern that many are not being identified using current practices. We evaluated population-based MSI screening of CRC in young patients as a means of ascertaining mutation carriers. CRC diagnosed in patients aged <60 years were identified from pathology records. No prior information was available on family history of cancer. PCR techniques were used to determine MSI in the BAT-26 mononucleotide repeat and mutation in the BRAF oncogene. Loss of MLH1, MSH2, MSH6 and PMS2 protein expression was evaluated in MSI+ tumours by immunohistochemistry. MSI+ tumours were found in 105/1,344 (7.8%) patients, of which 7 were excluded as possible Lynch syndrome because of BRAF mutation. Of the 98 "red flag" cases that were followed up, 25 were already known as mutation carriers or members of mutation carrier families. Germline test results were obtained for 35 patients and revealed that 22 showed no apparent mutation, 11 showed likely pathogenic mutations and 2 had unclassified variants. The proportion of MSI+ cases in different age groups that were estimated to be mutation carriers was 89% (<30 years), 83% (30-39), 68% (40-49) and 17% (50-59). We recommend MSI as the initial test for population-based screening of Lynch syndrome in younger CRC patients, regardless of family history.

Entities:  

Mesh:

Year:  2009        PMID: 19072991     DOI: 10.1002/ijc.23863

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  26 in total

1.  MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer.

Authors:  María Dolores Giráldez; Francesc Balaguer; Luis Bujanda; Miriam Cuatrecasas; Jenifer Muñoz; Virginia Alonso-Espinaco; Mikel Larzabal; Anna Petit; Victoria Gonzalo; Teresa Ocaña; Leticia Moreira; José María Enríquez-Navascués; C Richard Boland; Ajay Goel; Antoni Castells; Sergi Castellví-Bel
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program.

Authors:  Aparna Mukherjee; Thomas J McGarrity; Francesca Ruggiero; Walter Koltun; Kevin McKenna; Lisa Poritz; Maria J Baker
Journal:  Hered Cancer Clin Pract       Date:  2010-11-22       Impact factor: 2.857

3.  Can a gastrointestinal pathologist identify microsatellite instability in colorectal cancer with reproducibility and a high degree of specificity?

Authors:  Eli Brazowski; Paul Rozen; Sara Pel; Ziona Samuel; Irit Solar; Guy Rosner
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

4.  De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.

Authors:  Ajay Goel; Thuy-Phuong Nguyen; Hon-Chiu E Leung; Takeshi Nagasaka; Jennifer Rhees; Erin Hotchkiss; Mildred Arnold; Pia Banerji; Minoru Koi; Chau-To Kwok; Deborah Packham; Lara Lipton; C Richard Boland; Robyn L Ward; Megan P Hitchins
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

5.  Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer : CRC in patients under 50 years of age.

Authors:  Vera Simone Schellerer; Susanne Merkel; Silke Christiane Schumann; Anne Schlabrakowski; Thomas Förtsch; Claus Schildberg; Werner Hohenberger; Roland Siegfried Croner
Journal:  Int J Colorectal Dis       Date:  2011-09-01       Impact factor: 2.571

6.  Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.

Authors:  Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Dallas English; Mark A Jenkins; Stine V Eriksen; Michael D Walsh; Rhiannon J Walters; Stephen N Thibodeau; Jenna Stewart; Susan Preston; Aung Ko Win; Louisa Flander; Driss Ait Ouakrim; Finlay A Macrae; Alex Boussioutas; Ingrid M Winship; Graham G Giles; John L Hopper; Melissa C Southey
Journal:  J Gastroenterol Hepatol       Date:  2017-02       Impact factor: 4.029

7.  A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.

Authors:  Lyn Schofield; Fabienne Grieu; Jack Goldblatt; Benhur Amanuel; Barry Iacopetta
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

8.  Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience.

Authors:  Trilokesh D Kidambi; Amie Blanco; Megan Myers; Peggy Conrad; Kate Loranger; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2014-06-06       Impact factor: 3.199

9.  Cancer survivors: familial risk perception and management advice given to their relatives.

Authors:  Francois Eisinger; Anne Deborah Bouhnik; Laetitia Malavolti; Anne Gaelle Le Corroller-Soriano; Claire Julian-Reynier
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

10.  Identifying Lynch syndrome.

Authors:  Albert de la Chapelle; Glenn Palomaki; Heather Hampel
Journal:  Int J Cancer       Date:  2009-09-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.